WO2014068506A3 - Compositions and methods for the treatment of autoimmune diseases - Google Patents

Compositions and methods for the treatment of autoimmune diseases Download PDF

Info

Publication number
WO2014068506A3
WO2014068506A3 PCT/IB2013/059805 IB2013059805W WO2014068506A3 WO 2014068506 A3 WO2014068506 A3 WO 2014068506A3 IB 2013059805 W IB2013059805 W IB 2013059805W WO 2014068506 A3 WO2014068506 A3 WO 2014068506A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compositions
treatment
methods
autoimmune diseases
Prior art date
Application number
PCT/IB2013/059805
Other languages
French (fr)
Other versions
WO2014068506A2 (en
Inventor
Mahesh Kandula
Original Assignee
Mahesh Kandula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahesh Kandula filed Critical Mahesh Kandula
Publication of WO2014068506A2 publication Critical patent/WO2014068506A2/en
Publication of WO2014068506A3 publication Critical patent/WO2014068506A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C07D473/38—Sulfur atom attached in position 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing autoimmune diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of rheumatoid arthritis, Crohn's disease, multiple sclerosis, systemic lupus erythematosus, dermatitis, ulcerative colitis, inflammatory bowel disease and other immune system related diseases.
PCT/IB2013/059805 2012-11-01 2013-10-31 Compositions and methods for the treatment of autoimmune diseases WO2014068506A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4564/CHE/2012 2012-11-01
IN4564CH2012 2012-11-01

Publications (2)

Publication Number Publication Date
WO2014068506A2 WO2014068506A2 (en) 2014-05-08
WO2014068506A3 true WO2014068506A3 (en) 2014-12-24

Family

ID=50628198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059805 WO2014068506A2 (en) 2012-11-01 2013-10-31 Compositions and methods for the treatment of autoimmune diseases

Country Status (1)

Country Link
WO (1) WO2014068506A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505776B2 (en) 2013-03-14 2016-11-29 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
ES2753361T3 (en) 2014-02-24 2020-04-08 Alkermes Pharma Ireland Ltd Sulfonamide and sulfinamide fumarate prodrugs and their use in the treatment of various diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056785A (en) * 1960-03-21 1962-10-02 Burroughs Weilcome & Co U S A Purine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056785A (en) * 1960-03-21 1962-10-02 Burroughs Weilcome & Co U S A Purine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505776B2 (en) 2013-03-14 2016-11-29 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases

Also Published As

Publication number Publication date
WO2014068506A2 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
WO2013175357A3 (en) Compositions and methods for treatment of inflammatory bowel disease
PH12015502055A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2015017813A3 (en) Inhibitors of the farnesoid x receptor and uses in medicine
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
PH12014502413A1 (en) Cyclic bridgehead ether dgat1 inhibitors
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
RU2015155585A (en) 4-ALKINYLIMIDAZOLE DERIVATIVE AND MEDICINAL PRODUCT INCLUDING SUCH DERIVATIVE AS AN ACTIVE INGREDIENT
PH12016500573A1 (en) Compound having somatostatin agonistic activity and pharmaceutical uses thereof
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2014068506A3 (en) Compositions and methods for the treatment of autoimmune diseases
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014091467A3 (en) Compositions and methods for the treatment of autoimmune diseases and inflammation
MX2016010771A (en) Compound binding to pparg but not acting as promoter and pharmaceutical composition for treating pparg-related diseases containing same as active ingredient.
WO2014037834A3 (en) Compositions and methods for treatment of inflammation and lipid disorders
WO2014122621A3 (en) Compositions and methods for the treatment of metabolic conditions and neuromuscular diseases
WO2017208088A3 (en) Compositions and methods for the treatment of parkinson's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13850893

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13850893

Country of ref document: EP

Kind code of ref document: A2